Global Chidamide Tablets Market Strategic Research Report

Scope of the Report

The global Chidamide Tablets market size is predicted to grow from US$ 147 million in 2025 to US$ 396 million in 2032; it is expected to grow at a CAGR of 12.4% from 2026 to 2032.

Chidamide is an oral subtype-selective histone deacetylase (HDAC) inhibitor independently developed in China, belonging to a novel class of epigenetic regulatory antitumor agents. It inhibits specific HDAC subtypes, regulates chromatin remodeling and gene expression, induces cell cycle arrest, apoptosis and differentiation of tumor cells, and activates the body’s antitumor immunity. It is mainly indicated for relapsed or refractory peripheral T-cell lymphoma and is continuously expanding applications in solid tumors and combination immunotherapy, representing the first original Chinese antitumor drug granted orphan drug designation by the U.S. FDA and achieving international industrialization.In 2025, global Chidamide production reached approximately 38 million bottles

Chidamide occupies a distinct niche in the global oncology market as a first-in-class, oral, subtype-selective HDAC inhibitor, representing a landmark for China’s innovative pharmaceutical industry. Its market trajectory is shaped by strong clinical positioning in rare hematologic malignancies, strategic expansion into broader cancer indications, and progressive international adoption. Driven by the unmet need for targeted therapies in lymphoma and the growing integration of epigenetic modulators into standard treatment regimens, the market demonstrates steady expansion, supported by favorable regulatory pathways and increasing clinical acceptance. Competitive dynamics remain focused on differentiation via mechanism of action and safety profile, while long-term growth hinges on successful penetration of new therapeutic areas and sustained geographic expansion beyond its core market

Key Questions Addressed in this Report

What is the 10-year outlook for the global Chidamide Tablets market?

What factors are driving Chidamide Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Chidamide Tablets market opportunities vary by end market size?

How does Chidamide Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Chidamide Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 5 mg
• 20 mg

Segment by Combination Therapy

• Combination With Aromatase Inhibitors
• Combination With CD20 Monoclonal Antibodies

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Peripheral T-Cell Lymphoma
• Breast Cancer
• Diffuse Large B-Cell Lymphoma
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Chidamide Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Peripheral T-Cell Lymphoma, Breast Cancer, Diffuse Large B-Cell Lymphoma evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact